AI-generated analysis. Always verify with the original filing.
CytoSorbents Corporation issued a press release announcing financial results for the fourth quarter and full year ended December 31, 2025, reporting full-year revenue of $37.1 million, up 4% from $35.6 million in 2024, and net loss of $8.2 million or $0.13 per share. Highlights include $2.5 million proceeds from an amended credit facility, Q4 cost reduction program, over 300,000 cumulative CytoSorb treatments, and ongoing FDA discussions for a new DrugSorb-ATR De Novo application.
Event Type
Disclosure
Mandatory
Variant
8-K
. Results of Operations and Financial Condition. On March 25, 2026, CytoSorbents Corporation issued a press release announcing its financial results for the qua
Regulation FD Disclosure. The information set forth above in Item 2.02 of this Current Report on Form 8-K is incorporated herein by reference.* Item 9.01 Exhibi
| Metric | Value | Basis |
|---|---|---|
| Revenue | $37.10 | |
| Gross Margin | 71% | |
| Operating Loss | $14.70 | |
| Net Loss | $8.20 | |
| EPS | $-0.13 | |
| Revenue | $9.20 | |
| Gross Margin | 74% | |
| Net Loss | $5.50 | |
| EPS | $-0.09 |